A 65-year-old patient with high-risk myelofibrosis, splenomegaly, normal renal function and disease-related symptomatology is being considered to receive ruxolitinib for the first time. What dose would you initiate in each of the following scenarios (or would you not use it)?
| Platelet count | Hgb | WBC |
What treatment would you usually recommend for patients whose MF is asymptomatic but who have anemia?
Which treatment would you most likely initiate for a 65-year-old patient with intermediate-2 myelofibrosis, splenomegaly and significant disease-related symptomatology who has already received EPO and danazol:
| Platelet count | Hgb | WBC |
| 220,000/µL |
What is the role of iron chelation for patients with MF who have frequent transfusion requirements?
How common is the occurrence of hydroxyurea-related leg ulcers?
Is hydroxyurea considered leukemogenic?
Is there cross-resistance between ruxolitinib and other JAK2 inhibitors?
OVERVIEW OF ACTIVITY
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses and other practitioners involved in the management of myelofibrosis.

In what situations, if any, do you recommend allotransplant to patients with MF?
Presently, how often do you recommend splenectomy to patients with MF?
Based on your clinical experience, which of the following disease states is most often confused with a diagnosis of myelofibrosis (MF)?